- ISPOR Latin America Summit 2019
ISPOR Latin America 2019
- Exhibits & Sponsorship
ISPOR Europe 2019
- Abstract Submission
- Short Courses
- Exhibits & Sponsorship
ISPOR Summit 2019
- ISPOR 2019
- ISPOR Warsaw 2019
- ISPOR Europe 2018
- ISPOR Summit 2018
- ISPOR Dubai 2018
- ISPOR Asia Pacific 2018
- ISPOR 2018
- ISPOR Europe 2017
- ISPOR Latin America 2017
- ISPOR Asia Pacific 2016
- Submit Abstract
- Exhibits & Sponsorships
- Awards & Grants
- Upcoming Conferences
Education & Training
- In-Person Training
- Introduction to Outcomes Research
- Introduction to Systematic Reviews & Meta-Analysis
- Systematic Review & Meta-Analysis: Applications
- Introduction to Pharmacoeconomics
- Cost-of-Illness/Cost-Estimation (COI/CE)
- Cost-Minimization/Cost-Consequence (CMA/CCA)
- Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis (CUA)
- Modeling Health Care Costs – Part I: Characteristics of Health Care Costs
- Modeling Health Care Costs – Part II: Methods and Guidelines for Estimating Health Care Costs
- Modeling Health Care Costs – Part III: Estimation from Censored Data
- Introduction to Budget Impact Analysis (BIA) - Part I
- Introduction to Budget Impact Analysis (BIA) - Part II
- Markov Model Toolkit: Concepts, Assumptions and Examples
- An Introduction to Choice-Based Conjoint Analysis (Discrete Choice Experiments)
- Health-Related Quality of Life (HRQOL) – Basics
- Patient Reported Outcomes: Analysis and Interpretation
- Patient Reported Outcomes: Instrument Development
- Item Response Theory: A Conceptual Introduction
- Preparing for Multinational Clinical Trials: Translation and Cultural Adaptations of PRO Measures
- Evidence Generation for Patient Reported Outcome (PRO) Label Claims (FDA Requirements)
- Intermediate Retrospective Observational Study - Propensity Scoring Methods
- Use of Public Survey Data in Health Outcomes Research
- Using RWE to Improve Healthcare Decision-making in Asia Pacific
- Top 10 HEOR Trends of 2019
- The Use of MCDA for HTA Agencies
- MCDA - How to Guide of Different Methods for Assessment of Rare Disease HT
- Virtualizing Long-Term Follow-Up Studies for Gene Therapy Products
- Is the FDA's New Guidance a Watershed Moment for Real-world Evidence?
- Topics in Evaluating the Cost-Effectiveness of Gene Therapies
- Distance Learning
ISPOR is strongly committed to diversity. The Society’s Strategic Plan and core values embrace excellence through encouragement and acceptance of diverse ideas, cultures, and disciplines. Research submissions are encouraged from all stakeholders and are evaluated based on merit. ISPOR also aims to reflect the diversity of its membership in all endeavors and encourages consideration of diversity in abstract submissions. Diversity dimensions include (but not limited to) gender, career stage, ethnicity, race, education, sexual orientation, region/geographic location, physical disability, and religion. Additional information can be found at the Society’s Diversity Policy.
- Abstract submissions are invited for Research abstracts, Issue Panel proposals, and Workshop proposals.
- All research abstract, workshop and issue panel proposal submissions and presentations must be in English (except for ISPOR Latin America Conferences).
- All research abstract, workshop and issue panel proposal submissions and presentations must not promote any product or service.
- Registration is required for all presenters.
- Expenses associated with submissions and presentations are the responsibility of the presenter.
- The presenters of research are required to disclose financial support. Abstract review will NOT be based on this information.
- All submissions, excluding title and author information, should be no longer than 300 words.
- The use of tables and graphs in your research abstract submission, workshop or issue panel proposals, are not allowed.
- Generic names should be used for technologies (drugs, devices), not trade names.
Abstract Submission Examples